NEU 2.81% $18.65 neuren pharmaceuticals limited

Ann: Q4 2021 quarterly activity and cash flow report, page-3

  1. 97 Posts.
    lightbulb Created with Sketch. 13
    I guess the highlights are:
    - discussions with potential partners for trof ex-NA progressing, with strong interest received from multiple parties
    - Revised Angelman syndrome protocol has been submitted to FDA, Phelan-McDermid and Pitt Hopkins protocols to be submitted shortly
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.